Pandemic COVID-19, an update of current status and new therapeutic strategies
A Vitiello, R La Porta, U Trama, F Ferrara, A Zovi… - Naunyn-Schmiedeberg's …, 2022 - Springer
The global COVID-19 pandemic is underway. In recent weeks, several countries throughout
the globe, and particularly in Europe, have experienced an exponential increase in the …
the globe, and particularly in Europe, have experienced an exponential increase in the …
What will be the role of molnupiravir in the treatment of COVID-19 infection?
A Vitiello, V Troiano, R La Porta - Drugs & Therapy Perspectives, 2021 - Springer
The global COVID-19 pandemic is currently underway. To date, there are approximately
4.55 million deaths and 219 million people infected [1]. The massive vaccination campaign …
4.55 million deaths and 219 million people infected [1]. The massive vaccination campaign …
[HTML][HTML] The emergence of powerful oral anti-COVID-19 drugs in the post-vaccine era
The quest for effective drugs to treat COVID-19 has been a priority since the outbreak of the
disease. The clinical application of remdesivir has been greatly restricted by the need for …
disease. The clinical application of remdesivir has been greatly restricted by the need for …
A clinical insight on new discovered molecules and repurposed drugs for the treatment of COVID-19
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began churning out
incredulous terror in December 2019. Within several months from its first detection in …
incredulous terror in December 2019. Within several months from its first detection in …
COVID-19 therapeutics for nonhospitalized patients
RT Gandhi, PN Malani, C Del Rio - Jama, 2022 - jamanetwork.com
Substantial progresshas been made in therapeutics for nonhospitalizedpatientswithCOVID-
19, butsupplyofand access to treatment remain limited. This Viewpoint summarizes currently …
19, butsupplyofand access to treatment remain limited. This Viewpoint summarizes currently …
COVID-19 and the promise of small molecule therapeutics: Are there lessons to be learnt?
WS Ho, R Zhang, YL Tan, CLL Chai - Pharmacological Research, 2022 - Elsevier
Abstract The coronavirus disease 2019 (COVID-19) pandemic had grounded the world to a
standstill. As the disease continues to rage two years on, it is apparent that effective …
standstill. As the disease continues to rage two years on, it is apparent that effective …
Comparative evaluation of authorized drugs for treating Covid‐19 patients
Abstract Background and Aims Vaccines are the first line of defense against coronavirus
disease 2019 (Covid‐19). However, the antiviral drugs provide a new tool to fight the Covid …
disease 2019 (Covid‐19). However, the antiviral drugs provide a new tool to fight the Covid …
Antiviral activity of molnupiravir against COVID-19: a schematic review of evidences
S Singla, S Goyal - Bulletin of the National Research Centre, 2022 - Springer
Background The study was aimed at encapsulating the evidence of in vitro and in vivo
antiviral activities of molnupiravir and its active form against highly pathogenic SARS-CoV-2 …
antiviral activities of molnupiravir and its active form against highly pathogenic SARS-CoV-2 …
Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19
GR Painter, MG Natchus, O Cohen, W Holman… - Current opinion in …, 2021 - Elsevier
Highlights•Molnupiravir is a broad acting, oral antiviral versus SARS-CoV-2, flu, Ebola and
others.•Clinical development was greatly accelerated in response to the COVID19 …
others.•Clinical development was greatly accelerated in response to the COVID19 …
A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus
There is an urgent need for an effective, oral, direct-acting therapeutic to block transmission
of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and prevent progression …
of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and prevent progression …